Metformin to prevent metabolic complications associated with Olanzapine
This study is investigating metformin (Glucophage) for the prevention of weight gain, hypercholesterolemia and elevated blood sugar or diabetes that has been associated with the antipsychotic olanzapine (Zyprexa). These side effects negatively impact morbidity and mortality, impair quality of life and decrease compliance. Metformin, an established first line treatment for diabetes mellitus Type II, is well tolerated and does not cause hypoglycemia. Study patients will receive regular monitoring of blood sugar, cholesterol and weight. Study medication and olanzapine are provided at no cost. In addition, participants receive financial reimbursement at each study visit.
You may be eligible to participate in this study if you:
Have diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder or major depression with psychotic features
Be at least 18 years of age
Have no unstable medical problems
Begin treatment with olanzapine within 5 days of entering the study
You will be excluded from this study if you:
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.